- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02116959
Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma
A Pilot Study Evaluating the Safety of Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Newly Diagnosed Advanced Intra-Ocular Retinoblastoma
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
California
-
San Francisco, California, Vereinigte Staaten, 94143
- University of California, San Francisco
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age greater than or equal to 3 months up to 18 years.
- Intraocular retinoblastoma not previously treated with systemic chemotherapy, radiation therapy, or IA therapy. Local retinal therapy such as laser photocoagulation and cryotherapy will be permitted.
- Unilateral or bilateral retinoblastoma (RB) patients are eligible
- Patients will be registered on study based on the local exam under anesthesia (EUA) done for diagnostic purposes prior to study entry. The EUA done at study entry should be done within 14 days prior to study entry
- Patients may have had enucleation of one eye, as long as the remaining eye meets the eligibility criteria
- Involved eye(s) must meet the definition for International Classification of Retinoblastoma
For unilateral retinoblastoma (see Appendix 1 for International Classification of Retinoblastoma):
- Group A eye that has failed local therapy
- Group B eye that has failed local therapy
- Group C eye that has failed local therapy
- Group D eye
- Group E eye that is not buphthalmic, is not planned for enucleation after first cycle of chemotherapy, and is in a child less than 1 year of age
For bilateral retinoblastoma (see Appendix 1 for International Classification of Retinoblastoma):
- Group A and Group A eyes that have failed local therapy
- Group A and Group B eyes that have failed local therapy
- Group A and Group C eyes
- Group A and Group D eyes
- Group A and Group E eyes in which the Group E eye is not planned for enucleation after first cycle of chemotherapy
- Group B and Group B eyes that have failed local therapy
- Group B and Group C eyes
- Group B and Group D eyes
- Group B and Group E eyes in which the Group E eye is not planned for enucleation after first cycle of chemotherapy
- Group C and Group C eyes
- Group C and Group D eyes
- Group C and Group E eyes even if early enucleation is planned for the Group E eye.
- Group D and Group D eyes
- Group D and Group E eyes even if early enucleation is planned for the Group E eye.
- Group E and Group E eyes if at least one eye is not planned for enucleation.
- Adequate Renal Function defined as: creatinine clearance or radioisotope Glomerular filtration rate (GFR) ³ 70 milliliter (mL)/min/1.73 m2 OR a serum creatinine based on age and gender derived from the Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the Center for Disease Control (CDC).
Adequate hematological function defined as:
- Absolute Neutrophil Count > 1000/microliter
- Platelet Count > 100,000/microliter
Adequate liver function defined as total bilirubin should be less than or equal to 1.5 x upper limit of normal (ULN) for age and serum glutamic-oxaloacetic transaminase (SGOT) / aspartate aminotransferase (AST) and serum glutamic-pyruvic transaminase (SGPT)
/ alanine aminotransferase (ALT) < 5 x upper limit of normal (ULN) for age
- Adequate coagulation system as defined as an international normalized ratio (INR) of less than 1.4 and a partial thromboplastin time (PTT) of less than 34
- Women and men of child-bearing potential must agree to use adequate contraception such as hormonal or barrier method of birth control or abstinence prior to study entry and for the duration of study participation. Should the subject or the subject's partner become pregnant or suspect pregnancy while on protocol therapy, the treating physician must be informed immediately.
Exclusion Criteria:
Any evidence of extraocular retinoblastoma clinically or by magnetic resonance imaging (MRI) of brain and orbits with and without gadolinium. MRI may be done within 21 days prior to study entry.
1. Evidence of systemic metastases on bilateral bone marrow, lumbar puncture, bone scan (or Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) scan), and/or any other additional tests done at study entry.
- Patients who have previously been treated with chemotherapy (with the exception of second inclusion criteria) radiation therapy, or intra-arterial therapy.
- Eyes with tumors that are amenable to local therapy with laser or cryotherapy without threat to vision
- Any technical factor that would prohibit use of catheterization of the ophthalmic artery (e.g., small for age infant, untreatable allergy to contrast).
- Abnormal cerebral vasculature noted on MR angiography that would increase the risk of the procedure, including but not limited to an incomplete Circle of Willis. Other abnormalities that are less severe than an incomplete Circle of Willis will be reviewed by the study chair in consultation with a neuro-interventional radiologist.
- Any serious ongoing condition, such as an untreated infection or organ dysfunction.
- Patients receiving any medications or substances that are inhibitors or inducers of CYP450 enzyme(s) are ineligible.
- Pregnant women are excluded from this study due to potential for teratogenic or abortifacient effects of therapy. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother breastfeeding should be discontinued upon start of protocol therapy.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Cohort 1
Patients will receive alternating treatments beginning with systemic chemotherapy then followed by intra-arterial (IA) therapy. Bilateral retinoblastoma patients will be in Cohort 1. For bilateral Bilateral retinoblastoma patients where one eye is stage A or B and the other eye is C, D, or E, only the higher stage eye (C, D, E) will be treated with IA chemotherapy unless the stage A or B eye is not amenable or has failed local therapy. |
|
Experimental: Cohort 2
Patients will receive only intra-arterial (IA) therapy for more limited disease.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Adverse Event evaluation for newly diagnosed advanced retinoblastoma treated with melphalan therapy and systemic chemotherapy
Zeitfenster: Up to 2 years
|
Up to 2 years
|
Dose-Limiting Toxicity (DLT) and minimum tolerated dosing interval for combination IAM and carboplatin, vincristine, and etoposide (CEV).
Zeitfenster: Up to 2 years
|
Up to 2 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Response rates after IAM combined with systemic CEV in patients with newly diagnosed advanced intraocular retinoblastoma
Zeitfenster: Up to 2 years
|
Up to 2 years
|
Ocular event free survival with the use of combination IAM therapy and systemic CEV in this patient population.
Zeitfenster: Up to 2 years
|
Up to 2 years
|
Visual outcomes using a standardized age based assessment
Zeitfenster: Up to 2 years
|
Up to 2 years
|
Salvage rate with triple IA therapy after failure of IA melphalan
Zeitfenster: Up to 2 years
|
Up to 2 years
|
Ocular event free survival for unilateral retinoblastoma with IA chemotherapy only for Group C or Group A/B that failed local therapy.
Zeitfenster: Up to 2 years
|
Up to 2 years
|
Visual outcomes using a standardized age based assessment.
Zeitfenster: Up to 2 years
|
Up to 2 years
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
Collection of melphalan pharmacokinetics after intra-arterial administration to the retina
Zeitfenster: Up to 2 years
|
Up to 2 years
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Anuradha Banerjee, MD, University of California, San Francisco
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen nach histologischem Typ
- Neubildungen
- Neubildungen nach Standort
- Neubildungen, Drüsen und Epithelien
- Augenkrankheiten
- Erkrankungen der Netzhaut
- Neubildungen, Neuroepithel
- Neuroektodermale Tumoren
- Neoplasmen, Keimzelle und Embryonal
- Neubildungen, Nervengewebe
- Augenkrankheiten, erblich
- Neubildungen des Auges
- Neubildungen der Netzhaut
- Retinoblastom
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Enzym-Inhibitoren
- Antineoplastische Mittel
- Immunsuppressive Mittel
- Immunologische Faktoren
- Tubulin-Modulatoren
- Antimitotische Mittel
- Mitose-Modulatoren
- Antineoplastische Mittel, alkylierend
- Alkylierungsmittel
- Myeloablative Agonisten
- Antineoplastische Mittel, Phytogen
- Topoisomerase-II-Inhibitoren
- Topoisomerase-Inhibitoren
- Carboplatin
- Etoposid
- Melphalan
- Vincristin
Andere Studien-ID-Nummern
- 13087
- NCI-2015-01749 (Registrierungskennung: NCI Clinical Trials Reporting Program (CTRP))
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Vincristin
-
ECOG-ACRIN Cancer Research GroupRekrutierungWiederkehrende akute lymphoblastische Leukämie bei Erwachsenen | Wiederkehrende akute lymphoblastische Leukämie im Kindesalter | B Akute lymphoblastische Leukämie | Refraktäre akute lymphoblastische Leukämie | T Akute lymphoblastische Leukämie | Lymphoblasten 5 Prozent oder mehr der kernhaltigen...Vereinigte Staaten
-
Centre Oscar LambretSFCEAbgeschlossen
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); Spectrum Pharmaceuticals, IncBeendetWiederkehrende akute myeloische Leukämie bei ErwachsenenVereinigte Staaten
-
Shanghai Pharmaceuticals Holding Co., LtdRekrutierung
-
University of RegensburgAbgeschlossenMedulloblastomDeutschland
-
Societe Internationale d'Oncologie PediatriqueAbgeschlossenPrimäre Neoplasien des ZentralnervensystemsFrankreich, Vereinigtes Königreich, Italien, Deutschland, Schweiz, Belgien, Dänemark, Norwegen, Österreich, Kroatien, Polen, Portugal
-
Shanghai Children's Medical CenterRekrutierungLangerhans-Zell-HistiozytoseChina
-
M.D. Anderson Cancer CenterInex PharmaceuticalsAbgeschlossenWeichteilsarkom | Lymphom | Leukämie | Osteosarkom | Wilms-TumorVereinigte Staaten
-
MedinCell S.AAbgeschlossenCovid19Vereinigtes Königreich
-
Dorothy Sipkins, MD, PhDAcrotech Biopharma Inc.; AmgenZurückgezogenAkute lymphoblastische B-Zell-LeukämieVereinigte Staaten